Suppressing STAT5 signaling affects osteosarcoma growth and stemness
Abstract Osteosarcoma (OS) is the most common primary bone tumor that primarily affects children and adolescents. Studies suggested that dysregulation JAK/STAT signaling promotes the development of OS. Cells treated with pimozide, a STAT5 inhibitor suppressed proliferation and colony formation and i...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-020-2335-1 |
_version_ | 1818415974533038080 |
---|---|
author | Dharmalingam Subramaniam Pablo Angulo Sivapriya Ponnurangam Prasad Dandawate Prabhu Ramamoorthy Pugazhendhi Srinivasan Tomoo Iwakuma Scott J. Weir Katherine Chastain Shrikant Anant |
author_facet | Dharmalingam Subramaniam Pablo Angulo Sivapriya Ponnurangam Prasad Dandawate Prabhu Ramamoorthy Pugazhendhi Srinivasan Tomoo Iwakuma Scott J. Weir Katherine Chastain Shrikant Anant |
author_sort | Dharmalingam Subramaniam |
collection | DOAJ |
description | Abstract Osteosarcoma (OS) is the most common primary bone tumor that primarily affects children and adolescents. Studies suggested that dysregulation JAK/STAT signaling promotes the development of OS. Cells treated with pimozide, a STAT5 inhibitor suppressed proliferation and colony formation and induced sub G0/G1 cell cycle arrest and apoptosis. There was a reduction in cyclin D1 and CDK2 expression and Rb phosphorylation, and activation of Caspase-3 and PARP cleavage. In addition, pimozide suppressed the formation of 3-dimensional osteospheres and growth of the cells in the Tumor in a Dish lung organoid system. Furthermore, there was a reduction in expression of cancer stem cell marker proteins DCLK1, CD44, CD133, Oct-4, and ABCG2. More importantly, it was the short form of DCLK1 that was upregulated in osteospheres, which was suppressed in response to pimozide. We further confirmed by flow cytometry a reduction in DCLK1+ cells. Moreover, pimozide inhibits the phosphorylation of STAT5, STAT3, and ERK in OS cells. Molecular docking studies suggest that pimozide interacts with STAT5A and STAT5B with binding energies of −8.4 and −6.4 Kcal/mol, respectively. Binding was confirmed by cellular thermal shift assay. To further understand the role of STAT5, we knocked down the two isoforms using specific siRNAs. While knockdown of the proteins did not affect the cells, knockdown of STAT5B reduced pimozide-induced necrosis and further enhanced late apoptosis. To determine the effect of pimozide on tumor growth in vivo, we administered pimozide intraperitoneally at a dose of 10 mg/kg BW every day for 21 days in mice carrying KHOS/NP tumor xenografts. Pimozide treatment significantly suppressed xenograft growth. Western blot and immunohistochemistry analyses also demonstrated significant inhibition of stem cell marker proteins. Together, these data suggest that pimozide treatment suppresses OS growth by targeting both proliferating cells and stem cells at least in part by inhibiting the STAT5 signaling pathway. |
first_indexed | 2024-12-14T11:43:31Z |
format | Article |
id | doaj.art-5d310a6efbe6464b9de53da6369710ad |
institution | Directory Open Access Journal |
issn | 2041-4889 |
language | English |
last_indexed | 2024-12-14T11:43:31Z |
publishDate | 2020-02-01 |
publisher | Nature Publishing Group |
record_format | Article |
series | Cell Death and Disease |
spelling | doaj.art-5d310a6efbe6464b9de53da6369710ad2022-12-21T23:02:42ZengNature Publishing GroupCell Death and Disease2041-48892020-02-0111211510.1038/s41419-020-2335-1Suppressing STAT5 signaling affects osteosarcoma growth and stemnessDharmalingam Subramaniam0Pablo Angulo1Sivapriya Ponnurangam2Prasad Dandawate3Prabhu Ramamoorthy4Pugazhendhi Srinivasan5Tomoo Iwakuma6Scott J. Weir7Katherine Chastain8Shrikant Anant9Department of Cancer Biology, The University of Kansas Medical CenterDivision of Hematology and Oncology, Children’s Mercy HospitalDepartment of Cancer Biology, The University of Kansas Medical CenterDepartment of Cancer Biology, The University of Kansas Medical CenterDepartment of Cancer Biology, The University of Kansas Medical CenterDepartment of Cancer Biology, The University of Kansas Medical CenterDepartment of Cancer Biology, The University of Kansas Medical CenterDepartment of Cancer Biology, The University of Kansas Medical CenterDivision of Hematology and Oncology, Children’s Mercy HospitalDepartment of Cancer Biology, The University of Kansas Medical CenterAbstract Osteosarcoma (OS) is the most common primary bone tumor that primarily affects children and adolescents. Studies suggested that dysregulation JAK/STAT signaling promotes the development of OS. Cells treated with pimozide, a STAT5 inhibitor suppressed proliferation and colony formation and induced sub G0/G1 cell cycle arrest and apoptosis. There was a reduction in cyclin D1 and CDK2 expression and Rb phosphorylation, and activation of Caspase-3 and PARP cleavage. In addition, pimozide suppressed the formation of 3-dimensional osteospheres and growth of the cells in the Tumor in a Dish lung organoid system. Furthermore, there was a reduction in expression of cancer stem cell marker proteins DCLK1, CD44, CD133, Oct-4, and ABCG2. More importantly, it was the short form of DCLK1 that was upregulated in osteospheres, which was suppressed in response to pimozide. We further confirmed by flow cytometry a reduction in DCLK1+ cells. Moreover, pimozide inhibits the phosphorylation of STAT5, STAT3, and ERK in OS cells. Molecular docking studies suggest that pimozide interacts with STAT5A and STAT5B with binding energies of −8.4 and −6.4 Kcal/mol, respectively. Binding was confirmed by cellular thermal shift assay. To further understand the role of STAT5, we knocked down the two isoforms using specific siRNAs. While knockdown of the proteins did not affect the cells, knockdown of STAT5B reduced pimozide-induced necrosis and further enhanced late apoptosis. To determine the effect of pimozide on tumor growth in vivo, we administered pimozide intraperitoneally at a dose of 10 mg/kg BW every day for 21 days in mice carrying KHOS/NP tumor xenografts. Pimozide treatment significantly suppressed xenograft growth. Western blot and immunohistochemistry analyses also demonstrated significant inhibition of stem cell marker proteins. Together, these data suggest that pimozide treatment suppresses OS growth by targeting both proliferating cells and stem cells at least in part by inhibiting the STAT5 signaling pathway.https://doi.org/10.1038/s41419-020-2335-1 |
spellingShingle | Dharmalingam Subramaniam Pablo Angulo Sivapriya Ponnurangam Prasad Dandawate Prabhu Ramamoorthy Pugazhendhi Srinivasan Tomoo Iwakuma Scott J. Weir Katherine Chastain Shrikant Anant Suppressing STAT5 signaling affects osteosarcoma growth and stemness Cell Death and Disease |
title | Suppressing STAT5 signaling affects osteosarcoma growth and stemness |
title_full | Suppressing STAT5 signaling affects osteosarcoma growth and stemness |
title_fullStr | Suppressing STAT5 signaling affects osteosarcoma growth and stemness |
title_full_unstemmed | Suppressing STAT5 signaling affects osteosarcoma growth and stemness |
title_short | Suppressing STAT5 signaling affects osteosarcoma growth and stemness |
title_sort | suppressing stat5 signaling affects osteosarcoma growth and stemness |
url | https://doi.org/10.1038/s41419-020-2335-1 |
work_keys_str_mv | AT dharmalingamsubramaniam suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT pabloangulo suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT sivapriyaponnurangam suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT prasaddandawate suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT prabhuramamoorthy suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT pugazhendhisrinivasan suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT tomooiwakuma suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT scottjweir suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT katherinechastain suppressingstat5signalingaffectsosteosarcomagrowthandstemness AT shrikantanant suppressingstat5signalingaffectsosteosarcomagrowthandstemness |